CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-10 | BVF PARTNERS L P/IL Director | Returned to the company | −161,810 | 2,003,966 | ||
| 2025-01-10 | BVF PARTNERS L P/IL Director | Returned to the company | −22,740 | 347,970 | ||
| 2025-01-10 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +235,450 | 3,291,004 | ||
| 2025-01-10 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +161,810 | 2,627,590 | ||
| 2025-01-10 | BVF PARTNERS L P/IL Director | Grant or award · Pre-Funded Warrant | +22,740 | 336,288 | ||
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC 10% owner | Other disposition | −3,500,000 | 4,300,000 | ||
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC 10% owner | Other acquisition · Pre-Funded Warrant (right to buy) | +3,500,000 | 3,500,000 | ||
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +300,000 | $5.76 | $1.7M | 7,800,000 |
| 2024-12-17 | Graham G. Walmsley Director | Sale | −700,761 | $6.75 | $4.7M | 0 |
| 2024-12-17 | Graham G. Walmsley Director | Purchase | −700,761 | $6.75 | $4.7M | 1,408,875 |
| 2024-12-16 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise | +14,000 | $4.87 | $68K | 129,509 |
| 2024-12-16 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) | −14,000 | 112,840 | ||
| 2024-12-13 | Graham G. Walmsley Director | Sale | −700,761 | $6.75 | $4.7M | 0 |
| 2024-12-13 | Graham G. Walmsley Director | Purchase | +700,761 | $6.75 | $4.7M | 700,761 |
| 2024-12-11 | Harmon Cyrus Director | Sale | −7,958 | $8.66 | $69K | 764,319 |
| 2024-12-11 | Harmon Cyrus Director | Sale | −179 | $9.39 | $2K | 764,140 |
| 2024-12-11 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −13,314 | $8.66 | $115K | 598,633 |
| 2024-12-11 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −300 | $9.39 | $3K | 598,333 |
| 2024-12-11 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Sale | −14,202 | $8.66 | $123K | 115,829 |
| 2024-12-11 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Sale | −320 | $9.39 | $3K | 115,509 |
Page 6 of 11 · 207 trades